Physicians were open to using KSI-101 after eye drops and before steroid injections; Uveitis Specialists may use first-line in severe cases Note: 1 Cases tend to be more severe and bilateral warranting systemic immunosuppressants (e.g., methotrexate, adalimumab, tocilizumab) and often prescribed in coordination with a rheumatologist; 2 Majority of cases are resolved with anti-infective treatments; 3 Steroids cautiously introduced after infection control, some specialists may progress to IVT or oral steroids if inflammation persists, but do so cautiously; 4 KSI-101 placement in infectious ME is more variable, some physicians will use in place of steroids, others try to avoid ocular injections after recent infection, and others prefer drops / oral therapies that can be removed quickly in case infection re-emerges; IVT = Intravitreal Injections; ME = Macular Edema; NSAID = Non-Steroidal Anti- Inflammatory Drug; Source: Expert Interviews (JUN 2025) TREATMENT PARADIGM EVOLUTION • KSI-101 is generally considered early second line , but may be first-line in patients with more severe disease or contra- indications to steroids Topical NSAIDs Topical steroids Systemic immunosuppressants 1 Topical NSAIDs Topical steroids Periocular steroid Periocular steroid Anti-infectives 2 MACULAR EDEMA SECONDARY TO INFLAMMATION Idiopathic Autoimmune-related Post-procedural Infectious IVT steroid injections Systemic immunosuppressants IVT steroid injections ILLUSTRATIVE Topical steroids 3 IVT or oral steroids 3 KSI-101 “... [I’d use Product X in] patients who fail my first line with topical therapy. I might think of this as second line, maybe instead of going to a triamcinolone injection or a dexamethasone implant ...” – Retina Specialist KSI-101 KSI-101 4 “... If they are younger, phakic, I will try [Product X] first ...” – Retina Specialist Placement certainty: Consensus Varied perspectives 118